Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combining bromhexine and spironolactone was effective in improving clinical outcomes and reducing viral load or hospitalization duration in patients with mild to moderate COVID-19.

This study used human stem cell-derived skin organoids to model EV-A71 infection, revealing that various skin cell types are susceptible to the virus and identifying a potential drug target and replication inhibitor, suggesting its utility for studying skin infectious diseases and drug screening.

In this study, researchers discovered that several compounds, including brequinar and 6-azauridine, exhibit significant anti-Zika virus activity using a high-throughput screen assay.

This report describes a case of alopecia universalis in a woman with hepatitis C linked to pegylated interferon alfa-2b and ribavirin therapy, with hair regrowth observed one year after discontinuation.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

This case report presents an HIV-1 patient who experienced osteosclerosis and new bone formation potentially due to long-term indinavir therapy and concurrent use of vitamin A, with symptoms reducing after switching to nelfinavir.

In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.

This study reported a drug-induced pityriasis rubra pilaris-like eruption in a patient treated with sorafenib, suggesting a possible effect of sorafenib on keratinocyte biology.

In this case study of a 64-year-old woman with kerion celsi caused by Microsporum canis, treatment with the oral antifungal fosravuconazole resulted in symptom resolution without scarring or side effects over 12 weeks, suggesting its potential effectiveness for various dermatomycoses.

This review discusses various presentations of drug-induced cutaneous eruptions, particularly those associated with interferon and ribavirin, and reports no new clinical findings.

In these initial clinical studies, NAP monotherapy showed significant reductions in HBsAg levels among patients with chronic HBV, suggesting potential as part of future combination therapies.

This review reports that nirmatrelvir-ritonavir has significant drug-drug interactions with many common dermatological medications, whereas molnupiravir may be an alternative therapy due to the absence of such interactions observed so far.

This article summarizes dermatologic adverse events in patients treated with afatinib in clinical trials and discusses strategies for managing these side effects, without providing new clinical results.

In this retrospective study, combining TACE with Donafenib showed promising results as a first-line treatment for Chinese patients with unresectable hepatocellular carcinoma, yielding a median progression-free survival of 12.8 months and a one-year overall survival rate of 87.5%, along with a favorable safety profile.

Sorafenib can cause a temporary skin condition that goes away after stopping the drug.

This study reported a 21% partial remission rate in patients with advanced soft tissue sarcomas treated with ifosfamide combination chemotherapy, with no complete remissions observed.

This case report identifies hand-foot and stump syndrome as a potential side effect of sorafenib therapy in a 47-year-old man with a leg amputation.

This report describes a case where oral valganciclovir treatment led to improved skin texture and hair regrowth in a patient with trichodysplasia spinulosa.

This case report details an occurrence of Vogt-Koyanagi-Harada disease during pegylated interferon-α2b and ribavirin therapy for chronic hepatitis C.

This study identified four drugs, including brequinar and abiraterone acetate, that inhibited SARS-CoV-2 infection in vitro, providing potential candidates for repurposing to treat COVID-19.

This study found that the antiviral drug daclatasvir significantly improved fibrosis and quality of life in a mouse model of recessive dystrophic epidermolysis bullosa, suggesting potential for treating this and other fibrotic diseases.

In this report, a case of a bullous lesion developed at the injection site in a patient treated with PEG-IFN-α-2a for chronic hepatitis C was described.

This case report describes a rare instance of alopecia universalis occurring eight weeks after discontinuing pegylated interferon α and ribavirin therapy, highlighting the need for awareness among healthcare providers.

This review outlines the main findings from clinical trials on teriflunomide's efficacy and safety for relapsing multiple sclerosis, noting clinical considerations and exploring its mechanisms based on various studies.

This case report describes irreversible alopecia universalis following discontinuation of Peg-IFN/RBV treatment for chronic hepatitis C, highlighting potential autoimmune side effects of interferon-based therapies.

This study found that sorafenib was active against desmoid tumors, with 25% of patients achieving a partial response and 70% maintaining stable disease.

This study found that combining sorafenib with Platycladus orientalis leaf extract effectively suppressed cervical cancer cell growth by increasing tumor suppressor gene expression and reducing anti-apoptotic gene expression, suggesting a potential rationale for further clinical trials.

This study suggests that human lymphoblastoid interferon, with or without prednisolone pretreatment, may be an effective and safe treatment option for hepatitis B in Oriental patients compared to placebo.